Segmentation by Disease Type (Parkinson’s disease, Schizophrenia, Alzheimer’s disease, and Others); by Drug Type {Galantamine, Benzodiazepines (Diazepam, Clonazepam, Lorazepam, and Others), Barbiturates (Methohexital, Phenobarbital, and Secobarbital), Amantadine, Donepezil, Levodopa, and Others}; and by End-User (Hospital, Pharmacy, and Others) – Global Demand Analysis & Opportunity Outlook 2031
Buy Now
On the basis of geographical analysis, the global positive allosteric modulators market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Asia Pacific region is estimated to witness modest growth over the forecast period on the back of the increasing investment in development of healthcare sector in the region, along with growing health awareness amongst the population.
The market in the North America region is anticipated to gain the largest market share throughout the forecast period on account of the higher health awareness amongst the population, along with easy access of quality healthcare in the developed nations, such as, the United States. Moreover, the higher investment in the R&D activities in the region is further expected to boost the market growth. As per the World Bank data, 2.734% of GDP of North America was spend for R&D activities in 2018.
The global positive allosteric modulators market is further classified on the basis of region as follows:
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Our in-depth analysis of the global positive allosteric modulators market includes the following segments:
By Disease Type
By Drug Type
By End-User
Growth Drivers
Challenges
February 16, 2022: Acadia Pharmaceuticals Inc. announced the FDA submission of supplemental New Drug Application (sNDA) for Pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.
June 11, 2020: Interim HealthCare Inc., launched a free dementia caregiver’s guide for homecare for patients living with dementia or Alzheimer’s disease.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Ans: The increasing prevalence of Parkinson’s disease, schizophrenia, Alzheimer’s disease, and other mental disorder is estimated to boost the market growth.
Ans: The market is anticipated to attain a significant CAGR over the forecast period, i.e., 2022 – 2031.
Ans: Poor adoption of advanced technology in low-income regions, along with side effects associated with the drugs are estimated to hamper the market growth.
Ans: The North America region is anticipated to provide more business opportunities over the forecast period owing to the high investment in R&D activities in the region.
Ans: The major players in the market are Eli Lilly and Company, Novartis AG, Bayer AG, Sanofi-aventis Groupe, Abbott Laboratories, Johnson & Johnson Services, Inc., Merck & Co., Inc., Siemens Healthcare GmbH, and Pfizer Inc.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by disease type, drug type, end-user, and by region.
Ans: The Alzheimer’s disease segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
